From the start of next year onwards, Jacob Tolstrup will lead Lundbeck's sales and marketing activities across all of the pharmaceutical company's business areas when he takes on the role of chief commercial officer (CCO), the company reveals in a press release.
Peter Anastasiou, executive vice president for North America, has decided to leave the post at the end of the year to pursue another opportunity, the press release reports, meaning that Tolstrup can take on this market alongside the markets in the rest of the world, which he is already responsible for. Anastasiou has been the person responsible for the launch of migraine drug Vyepti.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.